Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.

Publication ,  Journal Article
Ogura, Y; Jaffe, GJ; Cheung, CMG; Kokame, GT; Iida, T; Takahashi, K; Lee, WK; Chang, AA; Monés, J; D'Souza, D; Weissgerber, G; Gedif, K; Koh, A
Published in: Br J Ophthalmol
July 2022

PURPOSE: To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. DESIGN: HAWK was a global, 2-year, randomised, double-masked, multicentre phase III trial in participants with neovascular age-related macular degeneration. METHODS: Of the Japanese participants with PCV, 39 received brolucizumab 6 mg and 30 received aflibercept 2 mg. After 3 monthly loading doses, brolucizumab-treated eyes received an injection every 12 weeks (q12w) but were adjusted to q8w if disease activity was detected. Aflibercept-treated eyes received fixed q8w dosing. Mean change in best-corrected visual acuity (BCVA), the proportion of participants on q12w, retinal thickness, retinal fluid changes and safety were assessed to Week 96. RESULTS: Mean change in BCVA (early treatment diabetic retinopathy study (ETDRS) letters) from baseline to week 48/week 96 was+10.4/+11.4 for brolucizumab and +11.6/+11.1 for aflibercept. For brolucizumab-treated eyes, the probability of only q12w dosing after loading through week 48 was 76%, and 68% through week 96. Fluid resolution was greater with brolucizumab than aflibercept: respective proportions of eyes with intraretinal fluid and/or subretinal fluid were 7.7% and 30% at week 48% and 12.8% and 16.7% at week 96. Brolucizumab exhibited an overall well-tolerated safety profile despite a higher rate of intraocular inflammation compared with aflibercept. CONCLUSION: In Japanese eyes with PCV, brolucizumab q12w/q8w monotherapy resulted in robust and consistent BCVA gains that were comparable to q8w aflibercept dosing. Anatomical outcomes favoured brolucizumab over aflibercept, with 76% of brolucizumab participants maintained on q12w dosing after loading to week 48.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Br J Ophthalmol

DOI

EISSN

1468-2079

Publication Date

July 2022

Volume

106

Issue

7

Start / End Page

994 / 999

Location

England

Related Subject Headings

  • Visual Acuity
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ophthalmology & Optometry
  • Japan
  • Intravitreal Injections
  • Humans
  • Hawks
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ogura, Y., Jaffe, G. J., Cheung, C. M. G., Kokame, G. T., Iida, T., Takahashi, K., … Koh, A. (2022). Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol, 106(7), 994–999. https://doi.org/10.1136/bjophthalmol-2021-319090
Ogura, Yuichiro, Glenn J. Jaffe, Chui Ming Gemmy Cheung, Gregg T. Kokame, Tomohiro Iida, Kanji Takahashi, Won Ki Lee, et al. “Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.Br J Ophthalmol 106, no. 7 (July 2022): 994–99. https://doi.org/10.1136/bjophthalmol-2021-319090.
Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022 Jul;106(7):994–9.
Ogura, Yuichiro, et al. “Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.Br J Ophthalmol, vol. 106, no. 7, July 2022, pp. 994–99. Pubmed, doi:10.1136/bjophthalmol-2021-319090.
Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D’Souza D, Weissgerber G, Gedif K, Koh A. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022 Jul;106(7):994–999.

Published In

Br J Ophthalmol

DOI

EISSN

1468-2079

Publication Date

July 2022

Volume

106

Issue

7

Start / End Page

994 / 999

Location

England

Related Subject Headings

  • Visual Acuity
  • Treatment Outcome
  • Tomography, Optical Coherence
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ophthalmology & Optometry
  • Japan
  • Intravitreal Injections
  • Humans
  • Hawks